GST will benefit the consumers as the prices of diabetes and cancer reduces

  • News
  • June 30, 2017

New Delhi : The National Pharmaceutical Pricing Authority (NPPA) announced provisional ceiling price of 761 medicines including drugs to treat Cancer, HIV, Diabetes and antibiotics. To make implementation of GST smooth, NPPA have worked out to release the provisional ceiling prices of 761 formulations.

Pharmaceutical firms asked by NPPA to go through the list and inform them by June 29 if any correction has to be made. Prices will make public after GST implementation.

NPPA said the expected tax range of 2-3 percent after the rollout of the new indirect tax, depending on the states.  Prices of the anti-cancer drugs like Bortezomib, Docetaxel and Gemcitabine have been reduced in the provisional list.

The goods and services tax (GST), is the biggest indirect tax reform and definitely help patients of diabetes and cancer patients who need medicines on regular basis.

The price of the Trastuzumab injection pack used to treat Breast will be down at Rs 54,582.25 after July 1, was Rs 56,912.83 earlier. Other anti-cancer drugs like Bortezomib, Docetaxel and Gemcitabine have been reduced in the shared list.

In short, the cancer and diabetes patients will get benefit after GST implementation.

  • Related Posts

    MedTech Zone AMTZ Puts Vizag on the Science Map of India

    Vizag Science &Technology Cluster rated as one of the India’s Strategic Innovation Hubs Visakhapatnam, June 28 – In a significant boost to Vizag’s growing scientific stature, the Andhra Pradesh MedTech…

    • News
    • May 27, 2025
    • 297 views
    Ramping Up Community for JeevanRaksha during Disasters

    CBDM India 2025 will Champion Health Resilience and Local Response Bengaluru: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises—including…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Trump pressures 17 pharma CEOs to cut US drug prices

    Trump pressures 17 pharma CEOs to cut US drug prices

    Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

    Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

    Karnataka issues order to merge Ayush drug dept with State FDA

    Karnataka issues order to merge Ayush drug dept with State FDA

    Orchid Pharma buyback rights to novel antibiotic; stock up 5%

    Orchid Pharma buyback rights to novel antibiotic; stock up 5%